Lucan · Conditions

Developmental milestones and red flags

Australian guidance: RACGP Child Development + Developmental Surveillance Pathway

1. Definition and epidemiology

Developmental delay is diagnosed when milestones are not met in one or more domains: social, emotional, communication, cognition, fine motor, or gross motor. Developmental disability refers to functional impairment in a child's physical, cognitive, language, or behavioural capacities. In Australia, approximately one in five children are developmentally vulnerable in at least one domain at school entry, and 7.4% of children aged 0 to 14 years have some level of disability, with intellectual disability being the most prevalent (4.3%). Autism spectrum disorder (ASD) affects 1 to 2% of the population globally, with a higher prevalence in males and increasing recognition in females due to historical diagnostic underdetection.

2. Pathophysiology

Child neurodevelopment proceeds through a sequence of genetically programmed but environmentally modifiable stages. Normal cortical maturation requires adequate synaptic pruning, myelination, and activity-dependent plasticity across sensorimotor, limbic, and association cortices during sensitive windows in the first three years of life (Robbins Ch 10). Disruption at any stage, whether from chromosomal abnormalities (trisomy 21, fragile X syndrome, 22q11.2 deletion), teratogen exposure (foetal alcohol spectrum disorder), perinatal hypoxic-ischaemic injury, or postnatal insults such as lead toxicity or severe neglect, can derail the typical developmental trajectory. In ASD specifically, the pathophysiology involves altered synaptic scaffolding proteins (neuroligins, neurexins, SHANK), disrupted excitatory-inhibitory balance in prefrontal and temporal cortices, and aberrant connectivity in social brain circuits including the superior temporal sulcus and the amygdala. Intellectual disability arises from reduced neuronal density, simplified dendritic arborisation, and impaired long-term potentiation. Early disruption tends to produce broader deficits because later-developing systems depend on earlier foundations.

3. Clinical presentation and diagnostic criteria

History should cover antenatal exposures (alcohol, valproate, rubella, cytomegalovirus), perinatal complications (prematurity, low birthweight, hypoxia), family history of developmental or learning disorders, and current parent or carer concerns. Examination spans all five developmental domains: gross motor (sitting unsupported by 9 months, walking independently by 18 months), fine motor (pincer grasp by 12 months), communication (babbling by 6 months, single words by 12 months, two-word phrases by 24 months), social or emotional (social smile by 6 weeks, joint attention by 12 months), and cognition or self-care. Red flags that warrant urgent referral include no babble or gesture by 12 months, no single words by 16 months, no two-word spontaneous phrases by 24 months, any loss of previously acquired language or social skills at any age, and absence of social smile. ASD is characterised by deficits in social communication and social interaction combined with restricted, repetitive patterns of behaviour and sensory sensitivities, with symptoms present from early childhood even if not recognised until later.

4. Investigations and AU-specific cutoffs

Assessment should proceed in a structured opportunistic fashion rather than via population-wide standardised screening, which the RACGP Red Book (10th edition, 2024) does not recommend for the general paediatric population. For children at elevated risk (Box 1 risk factors including prematurity, low birthweight, prenatal alcohol or drug exposure, infections, genetic characteristics, trauma, maltreatment, exposure to toxins, lead poisoning, low socioeconomic status), clinicians should assess milestone achievement opportunistically across social, emotional, communication, cognition, fine motor, and gross motor domains. The Parents Evaluation of Developmental Status (PEDS) tool, available from the Royal Children's Hospital Melbourne, provides a validated structured parent-report instrument used at intervals from birth to five years. Formal developmental assessment by a paediatrician or multidisciplinary team is warranted when concerns arise. Investigations may include: audiological testing (hearing loss is a common reversible cause of language delay), vision screening, thyroid function (congenital hypothyroidism is covered by newborn metabolic screening), chromosomal microarray or specific gene panel (fragile X polymerase chain reaction testing in males with intellectual disability), lead level if environmental exposure suspected, and metabolic screen if dysmorphic features or regression present. There is no specific serum biomarker for ASD; diagnosis is clinical using DSM-5 criteria applied by a trained clinician. Newborn universal hearing screening is a practice point recommendation in the RACGP Red Book for all Australian neonates.

5. Management

Management is guided by the domain and severity of delay, and is anchored to early intervention as the primary strategy. When developmental delays are confirmed following specialist assessment, outcomes are improved by evidence-based early intervention programs funded through the National Disability Insurance Scheme (NDIS) early childhood approach. Children who do not fully meet a formal developmental delay definition but still have developmental concerns are also eligible for this NDIS pathway. For ASD, management involves multidisciplinary input: applied behaviour analysis or naturalistic developmental behavioural interventions, speech pathology, occupational therapy for sensory and fine motor concerns, and educational support planning. The GP role includes facilitating timely referral, supporting the family through the diagnostic process, monitoring for co-occurring conditions, and coordinating care. Parents and carers should be advised on the importance of play, language exposure, joint attention activities, and responsive caregiving, particularly in the first 12 months, to optimise neurological development. For Aboriginal and Torres Strait Islander children, the RACGP recommends referral to the National Guide to a Preventive Health Assessment for Aboriginal and Torres Strait Islander People (child health chapter) for culturally appropriate guidance, given the higher rates of developmental vulnerability in this population.

6. Pharmacology and AU PBS notes

There is no disease-modifying pharmacotherapy for developmental delay or ASD. Pharmacological intervention targets co-occurring conditions:

Attention deficit hyperactivity disorder (ADHD) comorbid with ASD or intellectual disability: methylphenidate (Ritalin, Concerta) or dexamfetamine are Therapeutic Goods Administration (TGA) approved. PBS streamlined authority applies for children aged 6 years and over with a confirmed diagnosis by a paediatrician or psychiatrist (PBS item varies by formulation). Lisdexamfetamine (Vyvanse) is PBS-listed for ADHD from age 6.

Anxiety comorbid with ASD: selective serotonin reuptake inhibitors (fluoxetine, sertraline) may be used off-label; no specific PBS ASD indication exists. Sertraline (Zoloft, generic) and fluoxetine (Prozac, generic) are PBS-listed for childhood anxiety and obsessive-compulsive disorder.

Sleep disturbance in ASD: melatonin (Circadin 2 mg modified-release) is TGA-approved for sleep-onset insomnia in adults; paediatric use is off-label in Australia. Compounded immediate-release melatonin is widely used in practice.

Epilepsy comorbid with ASD or intellectual disability: first-line agents follow standard anticonvulsant guidelines per the epilepsy condition file; PBS items apply per specific seizure type and agent.

Antipsychotics (risperidone, aripiprazole) may be used for severe behavioural dysregulation in ASD when non-pharmacological strategies are insufficient; these require specialist initiation.

7. Complications and monitoring

Key complications of unrecognised or untreated developmental delay and ASD include academic underachievement, social isolation, mental health comorbidities (anxiety is present in up to 40% of individuals with ASD, depression increasingly prevalent in adolescence), and reduced adult independence and employment. Common co-occurring conditions in ASD include intellectual disability, specific learning disorders, speech and language disorders, epilepsy and seizure disorders, ADHD, anxiety, and depression.

Surveillance schedule for the GP:

Developmental review at standard well-child contacts: birth, 6 to 8 weeks, 4 months, 6 months, 12 months, 18 months, and 3 to 4 years, using the state or territory Child Personal Health Record (in Western Australia, the Purple Book). Opportunistic assessment at all contacts for children in the high-risk group. Following ASD diagnosis, monitor annually for emergence of anxiety, depression, sleep disorders, epilepsy, and academic function. Growth monitoring using WHO growth charts for children under 2 years and CDC or WHO age-specific body mass index charts for children aged 2 to 6 years at each well-child visit. Hearing review annually or when concerns arise, given the frequency of middle-ear disease contributing to language delay. Transition planning to adult services should commence no later than age 16 for young people with ASD or intellectual disability requiring ongoing NDIS support.

Written for Australian practice and grounded in the guidance named above. Study material only — not medical advice. Always check against current guidelines.